Abstract 3982
Background
A special role in the tumour progression is played by heterogeneous components of the microenvironment of tumours, premetastatic tumour niches, influencing which seems likely to change the disease course. Our purpose was to analyze some characteristics of the local cellular immunity in metastatic GC.
Methods
33 GC patients aged 30-80 years were divided into 2 groups: group 1 – M0, non-metastatic GC, n = 17, mean age 61.7±8.9 years (G2 – 11, G3 – 6 patients); group 2 – M1, GC with peritoneal and omentum metastases, n = 16, mean age 58.7±11.5 years (G2 – 7, G3 – 5, G4 - 3 patients). Tumours (T), peritumoral tissues (PT), omentum (O) and peritoneum (P) tissues were studied. Lymphocytes were determined by flow cytometry using FACSCantoII (BD) and T-, B-, NK antibody panels; quantitative content of DN (CD3+CD4-CD8-), DP (CD3+CD4+CD8+) T lymphocytes and regulatory (T-regs) T cells (CD4+CD25+CD127dim) was studied.
Results
Patients with M1 GC demonstrated increased CD3+ lymphocytic infiltration of T, PT, O and P tissues. IRI in M1 O was significantly higher than in M0 (1.95±0.3 vs 0.7±0.2), being similar in other tissues. Levels of DN lymphocytes were lower in O of M1, compared to M0 (7.7±2.5 vs 15.7±5.6, p ≤ 0.05). Contents of NK cells, NKT lymphocytes significantly decreased in O of M1 patients, compared to M0 (3.3≤1.1 vs 14.0≤2.3 and 1.7±0.5 vs 3.8±0.8, respectively). Higher levels of NKT lymphocytes were registered in M1 PT, compared to M0 (3.3±1.1 vs 1.3±0.4), as well as lower levels of NK cells in T (2.3±0.9 vs 5.33±0.2). Percentage of Treg lymphocytes in P and O were significantly lower in M1 than in M0 (respectively, 6.9±1.5 vs 12.6±4.9 and 5.9±1.3 vs 12.6±4.9). Higher amount of B lymphocytes was registered in all tissues of M1 patients, compared to M0, maximal in O (13.1±3.3 vs 3.4±1.5), T (23.5±5.1 vs 17.2±2.3) and P (8.2±3.4 vs 3.5±1.2), while in PT it was lower (15.7±4.2 vs 43.7±4.5).
Conclusions
GC metastasis to the omentum and peritoneum is characterized by a change in their immunological features – a decrease in the tissue level of NK and NKT lymphocytes, a loss in the prevalence of CD3+CD8+ due to an increase in the number of CD3+CD4+ cells, and an increase in the level of CD19 + (B2) lymphocytes. This probably contributes to the appearance of metastatic lesions in these organs in gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5345 - Short-term Clinical Outcomes of Robotic-Assisted Total Mesorectal Excision in Rectal Cancer after concurrent chemoradiotherapy
Presenter: Pojung Chen
Session: Poster Display session 2
Resources:
Abstract
5489 - Local immune status in cancer cell nests can be a predictor of survival for rectal cancer with neoadjuvant radiotherapy
Presenter: xijin lin
Session: Poster Display session 2
Resources:
Abstract
1653 - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study.
Presenter: Clémence Brun
Session: Poster Display session 2
Resources:
Abstract
5206 - Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer.
Presenter: Per Pfeiffer
Session: Poster Display session 2
Resources:
Abstract
2992 - Clinical impact of mucinous and poorly differentiated tumors on the outcome of patients with stage II colon cancer: a TOSCA subgroup analysis
Presenter: Gerardo Rosati
Session: Poster Display session 2
Resources:
Abstract
4753 - Exercise improved adjuvant treatment completion rates and treatment-related toxicities in colorectal cancer: A prospective pilot study
Presenter: Hong Jun Kim
Session: Poster Display session 2
Resources:
Abstract
2735 - Bevacizumab plus Oxaliplatin-Based Chemotherapy as Adjuvant Treatment for Colon Cancer (CC): Updated analysis of stage II disease from the AVANT Phase III Randomized trial by the GERCOR Group
Presenter: Aimery De Gramont
Session: Poster Display session 2
Resources:
Abstract
1843 - Multicenter Validation of the Postoperative Carcinoembryonic Antigen Combined Prognostic Model for Stage Ⅲ Colon Cancer
Presenter: Ji Zhu
Session: Poster Display session 2
Resources:
Abstract
2554 - Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey.
Presenter: Kaissa Ouali
Session: Poster Display session 2
Resources:
Abstract
3285 - Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Presenter: Philip Falk
Session: Poster Display session 2
Resources:
Abstract